After completing the 12-week induction study, your eligibility for the maintenance study will be evaluated based on your response to previous treatment.

You must show a reduction in Crohn’s Disease Activity Index (CDAI) of at least 100 points or have a score below 150 points.

Alternatively, you may qualify if you have an average daily stool frequency score of 3 or less and average abdominal pain score of 1 or less, with neither symptom worse than when you started treatment.

You will be randomly assigned to receive either ozanimod capsules or placebo capsules (capsules without active medication).

The capsules are to be taken by mouth.

Neither you nor your doctor will know which treatment you are receiving.

You will take the assigned medication for 52 weeks.

Regular assessments will monitor your CDAI score, abdominal pain, and stool frequency.

An examination of your intestines (endoscopy) will be performed to assess healing.

If you are taking corticosteroids, their use will be monitored during the last 12 weeks of the study.

Your health will be monitored throughout the study period.

Female participants must use effective birth control methods throughout the study and for 90 days after the last dose.

The study will track any worsening of symptoms, including an increase in CDAI score of 100 points or more above starting value and a score greater than 220.

At week 52, final assessments will be conducted to evaluate the effectiveness of the treatment.

These include measuring your CDAI score, examining your intestines, and evaluating tissue samples if taken.

The study will assess whether you achieved remission (improvement) of your Crohn’s disease symptoms.